Platform production processes simplify process development and make it easier to scale up effectively. Similarly, a platform analytical testing strategy reduces the time for assay development. We describe key considerations when building such an integrated platform for viral vectors, and propose near-term and future-state solutions.
In this webinar, you will learn:
- Suspension-based upstream viral vector platforms
- Analytical testing strategies for viral vector production
- Final filtration and cost-modeling for viral vectors
Speaker
David Loong, Ph.D.
Merck
Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy
David Loong is our senior consultant, novel modalities APAC, bioprocessing strategy. Previously, David held roles as a senior scientist in biotech startups encompassing cell & gene therapy process development services, mAb discovery, and preclinical development. He has an extensive track record providing contract research services as a senior research scientist at AMRI Global, and as a product custodian for API GMP manufacturing at GSK. He holds a Ph.D. in synthetic organic chemistry from the Australian National University and a BTech(Hons) from Massey University (NZ) specializing in chemistry and process engineering.
Pharma and biopharma manufacturing
- Viral Vector Upstream Processing
期间:1h
语言:English
场次 1:往期 April 20, 2021
如要继续阅读，请登录或创建帐户。
暂无帐户？